MetALD: new opportunities to understand the role of alcohol in steatotic liver disease.

Competing Interests: MT has received speaking fees from Siemens Healthcare, Norgine, Echosens, and Tillotts Pharma; consulting fees from GE Healthcare; and participated in advisory boards for ID Liver and Alcohol & Society. AK has served as speaker for Norgine, Siemens, and Nordic Bioscience; participated in advisory boards for Norgine and Siemens, all outside the submitted work; receives royalties from Gyldendal; and has received equipment, drugs, or other services from Norgine, Siemens, and Echosens. All other authors declare no competing interests.